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CONCLUSION: Young people are a population whose
dependency level is mainly low or moderate, a fact that
enables—with appropriate but generalised mobilization
(doctor, educator, pharmacist, family)—a smoking cessa-
tion attempt to succeed.
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OBJECTIVE: As part of an environment program 
(outcomes program) on smoking cessation, it seemed
interesting to study young smokers under the age of 25.
METHOD: A special questionnaire was distributed to
them via the “Student” supplement of a French regional
weekly newspaper (Tarn Libre), which they were asked
to return by post. RESULTS: The ﬁrst results concerned
the ﬁrst 50 questionnaires returned. Average age: 17.5
years; average weight: 56 kilos; average height: 1,67m.
In our sample, 92% were students, 86% declared them-
selves to be exposed to other people’s smoke and only
37% said they took part in a sporting activity. Age 
at which tobacco dependency began was 13 years; 
98% smoked cigarettes—versus 2% a cigar or pipe); the
average daily consumption was 10 cigarettes; of these,
65% wished to stop smoking, but only 38% had already
made an attempt at smoking cessation. Only 30%,
however, said that they had been asked spontaneously by
their doctor about their desire to stop smoking (minimum
advice) In the Fagerström test, 48% had low or no depen-
dency; 48% had moderate dependency and only 2% had
heavy dependency. CONCLUSION: This pilot study 
conﬁrmed that tobacco dependency is occurring at an
increasingly early age; that tobacco dependency in young
people is low or moderate, and that there is little 
management of tobacco dependency in young people by
doctors.
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OBJECTIVE: The objective of the health system is to
achieve an efﬁcient and equitable allocation of scarce
health resources. In this study, a particular social welfare
function was used to decide the optimal allocation of
resources between smoking cessation methods (medical
advice, nicotine gum and nicotine patches) for smo-
kers and 20–80mg/day lovastatin (HMG-CoA reductase
inhibitor) for individuals with hypercholesterolemia.
METHODS: Parameter epsilon determining the exact
form of the social welfare function is >0 when society has
aversion to inequality in the distribution of health gains
between two patient groups, while it is equal to 0 when
there is no aversion. This parameter was determined using
a questionnaire to assess preferences concerning the 
efﬁciency-equity trade-off in a group of health mana-
gers. Based on these preferences, a higher priority should
be given to the preventive intervention associated with 
a value of epsilon consistent with that from the social
welfare function. RESULTS: A value of epsilon = 1.6 was
obtained for the social welfare function. Values of epsilon
obtained for different preventive interventions were
2.9–1.8 for medical advice for smoking cessation and
20–80mg/day lovastatin, 0.9–0.15 for nicotine gum and
20–80mg/day lovastatin, and 0 for nicotine patch 
for smoking cessation and 20–80mg/day lovastatin. The
highest value of epsilon was obtained for the interven-
tion using medical advice for smoking cessation and 
20mg/day lovastatin for hypercholesterolemia, with 2.9
in men and 2.4 in women. A higher priority should 
be given to the intervention using medical advice for
smoking cessation and 20–80mg/day lovastatin for
hypercholesterolemia than to interventions using nicotine
substitution therapies and 20–80mg/day lovastatin.
CONCLUSION: Lovastatin treatment of hypercholes-
terolemia should have a higher priority than nicotine 
substitution therapies for smoking cessation based on
cost-effectiveness and the social welfare function.
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OBJECTIVES: New treatment recommendations 
describe aggressive lipid-lowering goals to maximize 
cardiovascular-event risk reduction for a broad popula-
tion. This analysis determined what statin doses would
be required to achieve treatment goals in a Canadian
population. METHODS: Canadian treatment guidelines
were reviewed and combined with population-based data
on blood lipid levels to determine the percentage reduc-
tion in LDL-C required to achieve treatment goals. Efﬁ-
cacy of statins was determined from the literature. The
statin dose required for patients to achieve LDL-C reduc-
tion goal was reported. RESULTS: The Canadian
1985–1990 Heart Health Surveys reported that 18% of
men and 17% of women had high blood lipid levels, with
a total cholesterol £6.2mmol/L (corresponding to an
approximate LDL-C level £4.7mmol/L). Canadian 
guidelines dictate that adults with very high risk of car-
diovascular events (those with a history of cardio-
